Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic gaucher disease leads to neurodegeneration

Human Molecular Genetics

Volumn 23, Issue 4, 2014, Pages 843-854

  Farfel Becker, Tamar ^a   Vitner, Einat B ^a   Kelly, Samuel L ^b   Bame, Jessica R ^b   Duan, Jingjing ^b   Shinder, Vera ^a   Merrill Jr , Alfred H ^b   Dobrenis, Kostantin ^c   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; GALACTOSYLCERAMIDE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; LACTOSYLCERAMIDE; PSYCHOSINE; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; BRAIN CELL; BRAIN CORTEX; BRAIN REGION; CELL INCLUSION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITE; DISEASE PREDISPOSITION; ELECTROSPRAY MASS SPECTROMETRY; ENDOPLASMIC RETICULUM; GAUCHER DISEASE; GENETIC RISK; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LIQUID CHROMATOGRAPHY; MACROGLIA; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; TRANSMISSION ELECTRON MICROSCOPY; UNFOLDED PROTEIN RESPONSE;

ANIMALS; BRAIN; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; LACTOSYLCERAMIDES; MICE; MICE, KNOCKOUT; NERVE DEGENERATION; NEURONS; PSYCHOSINE; SPHINGOMYELINS;

EID: 84893009529     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt468     Document Type: Article

References (53)

1. Farfel-Becker, T. and Futerman, A.H. (2010) Cellular pathogenesis in sphingolipid storage disorders: the quest for new therapeutic approaches. Clin. Lipidol., 5, 255-265.
2. Vitner, E.B., Platt, F.M. and Futerman, A.H. (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem., 285, 20423-20427.
3. Beutler, E. and Grabowski, G.A. (2001) Gaucher Disease. In Scriver, C., Beaudet, A.L., Valle, D., Sly, W.S. and Childs, B. (eds), The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New-York, Vol. 3, pp. 3635-3668.
4. Mignot, C., Doummar, D., Maire, I. and De Villemeur, T.B., French Type 2 Gaucher Disease Study Group. (2006) Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev., 28, 39-48.
5. Gupta, N., Oppenheim, I.M., Kauvar, E.F., Tayebi, N. and Sidransky, E. (2011) Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol. Dis., 46, 75-84.
6. Harris, C.M., Taylor, D.S. and Vellodi, A. (1999) Ocular motor abnormalities in Gaucher disease. Neuropediatrics, 30, 289-293.
7. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med., 361, 1651-1661.
8. Altarescu, G., Hill, S., Wiggs, E., Jeffries, N., Kreps, C., Parker, C.C., Brady, R.O., Barton, N.W. and Schiffmann, R. (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J. Pediatr., 138, 539-547.
9. Jmoudiak, M. and Futerman, A.H. (2005) Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol., 129, 178-188.
10. Nilsson, O. and Svennerholm, L. (1982) Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J. Neurochem., 39, 709-718.
11. Conradi, N.G., Sourander, P., Nilsson, O., Svennerholm, L. and Erikson, A. (1984) Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta. Neuropathol., 65, 99-109.
12. Tybulewicz, V.L., Tremblay, M.L., LaMarca, M.E., Willemsen, R., Stubblefield, B.K., Winfield, S., Zablocka, B., Sidransky, E., Martin, B.M. and Huang, S.P. (1992) Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature, 357, 407-410.
13. Orvisky, E., Sidransky, E., McKinney, C.E., LaMarca, M.E., Samimi, R., Krasnewich, D., Martin, B.M. and Ginns, E.I. (2000) Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr. Res., 48, 233-237.
14. Cabrera-Salazar, M.A., DeRiso, M., Bercury, S.D., Li, L., Lydon, J.T., Weber, W., Pande, N., Cromwell, M.A., Copeland, D., Leonard, J. et al. (2012) Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One, 7, e43310.
15. Orvisky, E., Park, J.K., LaMarca, M.E., Ginns, E.I., Martin, B.M., Tayebi, N. and Sidransky, E. (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab., 76, 262-270.
16. Schueler, U.H., Kolter, T., Kaneski, C.R., Blusztajn, J.K., Herkenham,M., Sandhoff, K. and Brady, R.O. (2003) Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage inGaucher disease type 2 and 3. Neurobiol.Dis., 14, 595-601.
17. Hernández, F. and Bueno, M. (1973) Infantile neurological Gaucher's disease in three siblings. An ultrastructural study. Virchows Arch A Pat
18. Kaye, E.M., Ullman, M.D., Wilson, E.R. and Barranger, J.A. (1986) Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann. Neurol., 20, 223-230.
19. Farfel-Becker, T., Vitner, E.B., Pressey, S.N.R., Eilam, R., Cooper, J.D. and Futerman, A.H. (2011) Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum. Mol. Genet., 20, 1375-1386.
20. Enquist, I.B., Lo Bianco, C., Ooka, A., Nilsson, E., Månsson, J.-E., Ehinger, M., Richter, J., Brady, R.O., Kirik, D. and Karlsson, S. (2007) Murine models of acute neuronopathic Gaucher disease. Proc. Natl Acad. Sci. USA, 104, 17483-17488.
21. Vitner, E.B., Farfel-Becker, T., Eilam, R., Biton, I. and Futerman, A.H. (2012) Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain, 135, 1724-1735.
22. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, C., Allman, J.M. et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab., 82, 192-207.
23. Willemsen, R., Tybulewicz, V., Sidransky, E., Eliason, W.K., Martin, B.M., LaMarca, M.E., Reuser, A.J., Tremblay, M., Westphal, H. and Mulligan, R.C. (1995) A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol. Chem. Neuropathol., 24, 179-192.
24. Pewzner-Jung, Y., Ben-Dor, S. and Futerman, A.H. (2006) When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J. Biol. Chem., 281, 25001-25005.
25. Merrill, A.H. (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev., 111, 6387-6422.
26. Laviad, E.L., Albee, L., Pankova-Kholmyansky, I., Epstein, S., Park, H., Merrill, A.H. and Futerman, A.H. (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem., 283, 5677-5684.
27. Ben-David, O. and Futerman, A.H. (2010) The role of the ceramide acyl chain length in neurodegeneration: involvement of ceramide synthases. Neuromolecular Med., 12, 341-350.
28. Sastry, P.S. (1985) Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res., 24, 69-176.
29. Bras, J., Singleton, A., Cookson, M.R. and Hardy, J. (2008) Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J., 275, 5767-5773.
30. Neumann, J., Bras, J., Deas, E., O'Sullivan, S.S., Parkkinen, L., Lachmann, R.H., Li, A., Holton, J., Guerreiro, R., Paudel, R. et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 132, 1783-1794.
31. Lee, R.E. (1968) The fine structure of the cerebroside occurring in Gaucher's disease. Proc. Natl Acad. Sci. USA, 61, 484-489.
32. Lee, R.E., Worthington, C.R. and Glew, R.H. (1973) The bilayer nature of deposits occurring in Gaucher's disease. Arch. Biochem. Biophys., 159, 259-266.
33. Peters, A., Palay, S.L. and Webster, H.D. (1991) The Fine Structure of the Nervous System. Oxford University Press, New York.
34. Farfel-Becker, T., Vitner, E.B. and Futerman, A.H. (2011) Animal models for Gaucher disease research. Dis. Model Mech., 4, 746-752.
35. Wolman, M. (1950) Staining of Lipids by the Periodic-Acid-Schiff Reaction. Proc. Soc. Exp. Biol. Med., 75, 583-585.
36. Bogoeva, B. and Petrusevska, G. (2001) Immunohistochemical and ultrastructural features of Gaucher's cells-five case reports. Acta Med. Croatica, 55, 131-134.
37. Norman, R.M., Urich, H. and Lloyd, O.C. (1956) The neuropathology of infantile Gaucher's disease. J. Pathol. Bacteriol., 72, 121-131.
38. Bennett, S.A., Stevenson, B., Staines, W.A. and Roberts, D.C. (1995) Periodic acid-Schiff (PAS)-positive deposits in brain following kainic acid-induced seizures: relationships to fos induction, neuronal necrosis, reactive gliosis, and blood-brain barrier breakdown. Acta Neuropathol., 89, 126-138.
39. Sun, Y., Zhang, W., Xu, Y.-H., Quinn, B., Dasgupta, N., Liou, B., Setchell, K.D.R. and Grabowski, G.A. (2013) Substrate compositional variation with tissue/region and Gba1 mutations in mouse models-implications for Gaucher disease. PLoS One, 8, e57560.
40. Lahiri, S. and Futerman, A.H. (2007) The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci., 64, 2270-2284.
41. Lloyd-Evans, E. (2003) Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem., 278, 23594-23599.
42. Adachi, M., Wallace, B.J., Schneck, L. and Volk, B.W. (1967) Fine structure of central nervous system in early infantile Gaucher's disease. Arch Pathol., 83, 513-526.
43. Takahashi, K., Terashima, K., Hakozaki, H., Naito, M. and Kojima, M. (1978) Pathomorphology of lysosomal storage inclusions in the reticuloendothelial cells of sphingolipidosis. Acta Histochem. Cytochem., 11, 286-315.
44. Cervos-Navarro, J. and Zimmer, C. (1990) Light microscopic and ultrastructural study on CNS lesions in infantile Gaucher's disease. Clin. Neuropathol., 9, 310-313.
45. Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M. and Futerman, A.H. (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem., 274, 21673-21678.
46. Farfel-Becker, T., Vitner, E., Dekel, H., Leshem, N., Enquist, I.B., Karlsson, S. and Futerman, A.H. (2009) No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet., 18, 1482-1488.
47. Lieberman, A.P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S.U. and Ballabio, A. (2012) Autophagy in lysosomal storage disorders. Autophagy, 8, 719-730.
48. Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A., Brandner, S., Waddington, S.N., Schapira, A.H.V. and Duchen, M.R. (2013)Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab., 17, 941-953.
49. Korschen, H.G., Yildiz, Y., Raju, D.N., Schonauer, S., Bonigk, W., Jansen, V., Kremmer, E., Kaupp, U.B. and Wachten, D. (2013) The Non-lysosomal-glucosidase GBA2 Is a Non-integral membrane-associated protein at the endoplasmic reticulum (ER) and golgi. J. Biol. Chem., 288, 3381-3393.
50. Meivar-Levy, I., Horowitz, M. and Futerman, A.H. (1994) Analysis of glucocerebrosidase activity usingN-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem. J., 303, 377-382
51. Bligh, E.G. and Dyer, W.J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol., 37, 911-917.
52. Shaner, R.L., Allegood, J.C., Park, H., Wang, E., Kelly, S., Haynes, C.A., Sullards, M.C. and Merrill, A.H. (2009) Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J. Lipid Res., 50, 1692-1707.
53. Sullards, M.C., Liu, Y., Chen, Y. and Merrill, A.H. (2011) Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tissue imaging mass spectrometry (TIMS). Biochim. Biophys. Acta, 1811, 838-853.